Tarsus Pharmaceuticals, Inc. (TARS)
80.28
+3.39
(+4.41%)
USD |
NASDAQ |
Nov 13, 16:00
80.40
+0.12
(+0.15%)
After-Hours: 19:59
Tarsus Pharmaceuticals Net Income (Quarterly) : -668.33M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -668.33M |
| June 30, 2026 | -18.55M |
| March 31, 2026 | -6.967M |
| December 31, 2025 | -8.373M |
| September 30, 2025 | -12.58M |
| June 30, 2025 | -20.34M |
| March 31, 2025 | -25.12M |
| December 31, 2024 | -23.11M |
| September 30, 2024 | -23.42M |
| June 30, 2024 | -33.29M |
| March 31, 2024 | -35.73M |
| December 31, 2023 | -41.90M |
| September 30, 2023 | -39.15M |
| June 30, 2023 | -31.42M |
| March 31, 2023 | -23.42M |
| Date | Value |
|---|---|
| December 31, 2022 | -13.60M |
| September 30, 2022 | -22.51M |
| June 30, 2022 | -5.743M |
| March 31, 2022 | -20.24M |
| December 31, 2021 | -14.85M |
| September 30, 2021 | -15.70M |
| June 30, 2021 | 6.299M |
| March 31, 2021 | 10.29M |
| December 31, 2020 | -11.47M |
| September 30, 2020 | -10.14M |
| June 30, 2020 | -3.25M |
| March 31, 2020 | -1.957M |
| December 31, 2019 | -1.412M |
| September 30, 2019 | -0.681M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Bristol Myers Squibb Co. | 2.162B |
| Amneal Pharmaceuticals, Inc. | 12.31M |
| Harmony Biosciences Holdings, Inc. | 48.20M |
| ANI Pharmaceuticals, Inc. | 32.72M |
| Corcept Therapeutics, Inc. | 124.49M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 194.57M |
| Total Expenses (Quarterly) | 862.90M |
| EPS Diluted (Quarterly) | -14.40 |
| Enterprise Value | 3.737B |
| Gross Profit Margin (Quarterly) | 92.86% |
| Profit Margin (Quarterly) | -343.5% |
| Earnings Yield | -18.91% |
| Normalized Earnings Yield | -7.068 |